EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome-associated factors in a molecularly defined cohort of central neurocytoma

Maja Krech, Amos Muench, Daniel Teichmann, Peter Kuzman, Abigail K Suwala, Franziska M Ippen, Michael Müther, Katharina J Weber, Katharina Wenger-Alakmeh, Julia Onken, Peter Vajkoczy, Felix Behling und 26 weitere

Acta Neuropathologica · 2025

DOI: 10.1007/s00401-025-02894-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2025. Verfasst von Maja Krech und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of, Freie Universität Berlin and Humboldt-Universität Zu Berlin,…. Hauptthemen laut MEDLINE: Neurocytoma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Deutschen Konsortium für Translationale Krebsforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central neurocytomas (CN) are intraventricular brain tumors predominantly occurring in young adults. Although prognosis is usually favorable, tumor recurrence is common, particularly following subtotal resection (STR). Currently, the risk of progression is evaluated using atypical features and an elevated Ki67 proliferation index. However, these markers lack consistent definitions, raising the need for objective criteria. Genome-wide DNA methylation profiles were examined in 136 tumors histologically classified as CN. Clinical/histopathological characteristics were assessed in 93/90 cases, and whole-exome sequencing was conducted in 12 cases. Clinical and molecular characteristics were integrated into a survival model to predict progression-free survival (PFS). A diagnosis of CN was epigenetically confirmed in 125 of 136 cases (92%). No DNA methylation subgroups were identified, but global DNA hypomethylation emerged as a hallmark feature of CN associated with higher recurrence risk. Risk stratification based on histological features of atypia and Ki67 proliferation index was not reproducible across neuropathologists. Hypomethylation at the FGFR3 locus, accompanied by increased FGFR3 protein expression, was observed in 97% of cases. Gross total resection was associated with significantly improved PFS compared to STR, while patients undergoing STR receiving radiotherapy had a better outcome ( p = 0.0001). Younger patients were identified as having a higher risk of recurrence ( p = 0.026). Patient age and treatment strategy were key factors associated with survival outcomes in this cohort. These findings underscore the importance of closer follow-up for younger patients and radiotherapy for STR cases. Furthermore, FGFR3 represents a hallmark feature and potential therapeutic target, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurocytomaBrain NeoplasmsHumansMaleFemaleAdultYoung AdultDNA MethylationMiddle AgedAdolescentCohort StudiesNeoplasm Recurrence, LocalPrognosis

Stichwörter der Autor:innen

DNA methylation profilingFGFR3NeurocytomaProgression-free survivalRadiotherapy

Autor:innen und Institutionen

  • Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of, Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of, Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Paul-Flechsig-Institute of Neuropathology, University Hospital Leipzig, Leipzig, Germany.
  • Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe
  • Deutschen Konsortium für Translationale Krebsforschung
  • Deutsche Stiftung für junge Erwachsene mit Krebs
  • Bundesministerium für Bildung und Forschung
  • Hertie Network of Excellence in Clinical Neuroscience
  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Krech, M., Muench, A., Teichmann, D., Kuzman, P., Suwala, A. K., Ippen, F. M., Müther, M., Weber, K. J., Wenger-Alakmeh, K., Onken, J., Vajkoczy, P., Behling, F., May, S. A., Ntoulias, G., Krauss, J. K., Atallah, O., Esmaeilzadeh, M., Mueller, W. C., Heppner, F. L., …, & Schweizer, L. (2025). Outcome-associated factors in a molecularly defined cohort of central neurocytoma. Acta Neuropathologica. https://doi.org/10.1007/s00401-025-02894-3

Vancouver

Krech M, Muench A, Teichmann D, Kuzman P, Suwala AK, Ippen FM, et al. Outcome-associated factors in a molecularly defined cohort of central neurocytoma. Acta Neuropathologica. 2025. doi:10.1007/s00401-025-02894-3

BibTeX
@article{Krech2025,
  author = {Krech, Maja and Muench, Amos and Teichmann, Daniel and Kuzman, Peter and Suwala, Abigail K and Ippen, Franziska M and Müther, Michael and Weber, Katharina J and Wenger-Alakmeh, Katharina and Onken, Julia and Vajkoczy, Peter and Behling, Felix and May, Sven-Axel and Ntoulias, Georgios and Krauss, Joachim K and Atallah, Oday and Esmaeilzadeh, Majid and Mueller, Wolf C and Heppner, Frank L and Radbruch, Helena and Dittmayer, Carsten and Stenzel, Werner and Koch, Arend and Capper, David and Kaul, David and Paulus, Werner and Plate, Karl H and Steinbach, Joachim P and Czabanka, Markus and Beschorner, Rudi and von Deimling, Andreas and Bockmayr, Michael and Neumann, Julia E and Brandner, Sebastian and Krieger, Teresa and Hartmann, Christian and Thomas, Christian and Schweizer, Leonille},
  title = {Outcome-associated factors in a molecularly defined cohort of central neurocytoma},
  journal = {Acta Neuropathologica},
  year = {2025},
  doi = {10.1007/s00401-025-02894-3}
}
Kostenlos starten →